Wegovy Tablets: UK’s First Oral GLP-1 Weight Loss TreatmentWegovy tablets mark a genuine turning point in weight loss treatment in the UK. The UK government has confirmed approval of the first oral GLP-1 tablet for weight loss, a semaglutide tablet, marking a significant milestone in weight management treatment. For patients reluctant to start injectable treatment, this needle-free option offers a welcome alternative. Our Weight Loss Clinics are closely following the rollout and can advise on the most appropriate option from our full range of weight loss treatments.
Curious whether Wegovy tablets could be right for you? Book a consultation today.

Wegovy tablets contain semaglutide, the same active ingredient found in the Wegovy injection. It belongs to a class of medications called GLP-1 receptor agonists, working by reducing appetite, increasing fullness, and slowing stomach emptying. Together, these effects help reduce calorie intake and support sustained weight loss. You can read more about semaglutide on the NHS website.
While both forms share the same active ingredient and mechanism, there are practical differences. The tablet is usually taken daily, and the injection once a week. Oral semaglutide has lower gut absorption, so the tablet typically requires a higher maximum dose of around 25mg daily, compared to 2.4mg weekly for the injection. Both have shown broadly similar outcomes, with average weight loss ranging from approximately 14 to 17% in trials.
Treatment usually begins at a low dose and is generally increased gradually over time up to a higher maintenance level. Oral semaglutide is typically taken after a period of fasting, usually with only a small amount of water, with food or drink generally avoided for a short period afterwards to support absorption. Your prescribing clinician will provide the exact dosing schedule specific to your treatment, as this can vary between individuals.
| Feature | Detail |
|---|---|
| Form | Daily tablet vs weekly injection |
| Active Ingredient | Semaglutide in both forms |
| Typical Maximum Dose | ~25mg daily (tablet) vs 2.4mg weekly (injection) |
| Administration | Tablet typically requires fasting and specific timing; injection is usually more flexible |
| Average Weight Loss | ~16.6% (tablet) vs broadly similar with injection |
Not sure whether tablets or injections are right for you?
Our clinical team will assess your suitability and explain your options as access expands. Contact Birmingham Weight Loss Clinics to find out more.
Wegovy tablets are typically prescribed for adults with a BMI of 30 or above, or 27 or above with a weight-related condition such as diabetes or hypertension. A full clinical assessment is required before any prescription is issued. Early access is expected primarily through private clinics, with demand likely to outstrip supply initially. Patients curious about real results have found it helpful to look at Wegovy before and after results from our existing injectable programme.
The side effect profile is similar to that of the injection, with the most common effects being nausea, vomiting, diarrhoea, and constipation. Less common but more serious risks include pancreatitis and gallbladder issues, and the medication is not suitable for everyone. Treatment is only used under medical supervision following a clinical assessment.
Given the high demand expected, we want to flag an important warning. Counterfeit and unlicensed weight loss medications are increasingly sold online, often at suspiciously low prices. Always obtain Wegovy tablets through a registered UK pharmacy with a genuine prescription. Our guide on buying Wegovy online in Birmingham explains how to do so safely.

Both contain semaglutide but are not the same product. Rybelsus is a lower-dose oral semaglutide approved for type 2 diabetes, while the Wegovy tablet is a higher-dose formulation approved for weight management and should not be used interchangeably.
Oral semaglutide generally has low gut absorption, which is why it is typically taken following a period of fasting and usually with only a small amount of water. Your prescribing clinician will explain the specific routine that applies to your treatment, as following it correctly can affect how well the medication is absorbed.
Yes. The UK government has confirmed that the oral semaglutide tablet has been approved for weight loss, making it the first GLP-1 tablet of its kind available in the UK. As with any newly approved medication, access is expected to expand gradually, with early availability primarily through private clinics.
Wegovy tablets represent an exciting, needle-free option for weight management, backed by clinical evidence and now approved in the UK. As access develops, Birmingham Weight Loss Clinics is committed to keeping patients informed and ensuring safe, clinically supervised treatment, whichever option suits them best.
The Wegovy Pill: Everything You Need to Know About the New Weight Loss TabletThe Wegovy pill is the latest development in weight loss treatment and one of the most significant breakthroughs in obesity medicine in years. It is an oral tablet containing semaglutide, the same active ingredient found in the Wegovy injection, and the first time a GLP-1 medication has been available in tablet form specifically for weight loss in the UK. For people who have been hesitant about injections, it opens up a genuinely new option. At Birmingham Weight Loss Clinics, our weight loss consultations are the best starting point for anyone curious about whether this treatment could be right for them.
Interested in the Wegovy pill? Book a consultation to discuss your options.
The Wegovy pill is a once-daily oral tablet containing semaglutide, a GLP-1 receptor agonist that mimics a naturally occurring hormone involved in appetite regulation. According to the UK government, the Wegovy pill is the first GLP-1 tablet approved specifically for weight loss in the UK, having received regulatory approval in June 2026. It works by reducing appetite, increasing feelings of fullness, and slowing stomach emptying.
Semaglutide is not a new ingredient, as it is also found in Wegovy injections, Ozempic (for type 2 diabetes), and Rybelsus (oral semaglutide for diabetes). What makes the Wegovy pill distinct is that it is the first oral formulation approved specifically for weight management. You can read more about semaglutide on the NHS website.

Clinical trials have shown average body weight loss of approximately 15 to 17% over around 64 weeks, placing the Wegovy pill among the most effective non-surgical weight loss treatments currently available. Results vary depending on dose, adherence, and lifestyle changes made alongside treatment. As with all GLP-1 treatments, it works best as part of a clinically supervised programme.
| Feature | Detail |
|---|---|
| Form | Oral tablet (pill) vs subcutaneous injection |
| Frequency | Daily (pill) vs weekly (injection) |
| Absorption | More variable with the pill; more consistent with the injection |
| Average Weight Loss | Broadly similar, approximately 15 to 17% in trials for both |
| Clinical Equivalence | Similar but not clinically identical; assessment needed to determine the most appropriate option |
Not sure whether the pill or injection is more suitable for you?
Our clinical team will assess your individual circumstances and help you understand all available options. Contact Birmingham Weight Loss Clinics to speak with us today.
The Wegovy pill is currently available privately through clinics and pharmacies in the UK, with high demand and waiting lists already reported at some providers. It is not yet available on the NHS, which is awaiting its own separate evaluation. As with weight loss injections, counterfeit products being sold online are a genuine concern, and the pill should only be obtained through a registered UK clinic or pharmacy following a clinical assessment. Our blog on Mounjaro vs Wegovy is a useful reference for comparing injectable and tablet options.
For patients already on a weight-loss injection who are considering switching to the Wegovy pill, understanding the approximate dose equivalences can be helpful context. The tables below provide estimated equivalences between injection and tablet doses, based on currently available guidance. These are best estimates only and should not be used to self-adjust or change your treatment without speaking to your prescribing clinician first. Any switch between forms of medication should always be managed by a healthcare professional.
Estimated Equivalent Strengths: Wegovy Injection to Wegovy Pill
| Wegovy Injection Dose | Wegovy Pill Dose (Estimated) |
|---|---|
| 0.25mg | 4mg |
| 0.5mg | 4mg |
| 1mg | 9mg |
| 1.7mg | 9mg |
| 2.4mg | 25mg |
| 7.2mg | 25mg |
Estimated Equivalent Strengths: Mounjaro Injection to Wegovy Pill
| Mounjaro Injection Dose | Wegovy Pill Dose (Estimated) |
|---|---|
| 2.5mg | 9mg |
| 5mg | 9mg |
| 7.5mg | 25mg |
| 10mg | 25mg |
| 12.5mg | 25mg |
| 15mg | 25mg |
The side effect profile is broadly similar to the injection, with the most commonly reported effects being nausea, vomiting, diarrhoea, and constipation. These are typical of GLP-1 medications and often improve over time. The pill is typically taken on an empty stomach with a specific fasting routine to support absorption, though your prescribing clinician will explain the exact approach for your treatment. It is not suitable for everyone and requires a clinical assessment before prescribing.

Both contain semaglutide, but they are different products. Rybelsus is a lower-dose oral semaglutide approved for type 2 diabetes, while the Wegovy pill is a higher-dose formulation approved for weight loss. They should not be used interchangeably.
The Wegovy pill is typically prescribed for adults with a BMI of 30 or above, or 27 or above with a weight-related health condition such as diabetes or hypertension. A clinical assessment is required to confirm suitability before any prescription is issued.
Mounjaro (tirzepatide) acts on both GLP-1 and GIP receptors, while the Wegovy pill acts on GLP-1 only. Trial data suggests Mounjaro produces slightly greater average weight loss at the highest dose. The most appropriate choice depends on individual suitability determined at consultation.
We are actively following the rollout of this new treatment. Book a consultation and our clinical team will advise on your options based on current availability and your individual health profile.
The Wegovy pill is a significant development for anyone who has wanted GLP-1 therapy without injections. At Birmingham Weight Loss Clinics, our clinical team is here to help you navigate your options and support you with a programme built around your individual needs.